{
    "nctId": "NCT04566458",
    "briefTitle": "RWD Study in HER2+ mBC Patients in Third-Line Therapy",
    "officialTitle": "Real-World Data Study in HER2+ Metastatic Breast Cancer Patients in Third-Line Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer Stage IV",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 63,
    "primaryOutcomeMeasure": "To describe treatment sequences of all lines of therapy received by HER2 + mBC patients in Canada",
    "eligibilityCriteria": "Inclusion Criteria:\n\nMale or female patients (\u226518 years of age)\n\nPatients with stage IV breast cancer\n\nPatients with HER2+ status in metastatic setting\n\nPatients that received at least two lines of active anti-cancer drugs due to disease progression.\n\nPatients that began third-line therapy prior to October 31, 2018.\n\nExclusion Criteria:\n\nPatients treated with an investigational anticancer agent in the \u2265 3rd line setting",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}